<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117807">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02089269</url>
  </required_header>
  <id_info>
    <org_study_id>iOM-01281</org_study_id>
    <nct_id>NCT02089269</nct_id>
  </id_info>
  <brief_title>Tumor Registry Pancreatic Cancer</brief_title>
  <official_title>Clinical Registry on Treatment Reality and Therapy Sequences in Patients With Metastatic or Locally Advanced Pancreatic Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry aims to collect and analyse information on the antineoplastic treatment of
      metastatic or locally advanced pancreatic cancer in daily routine practice in Germany. The
      registry will follow up patients for two years. It will identify common sequences of
      treatments used as well as changes in the treatment of the disease. Health-related quality
      of life will be analysed during the course of the treatment (PanLife). Based on the
      available data a prognostic score will be developed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Course of Antineoplastic Treatment</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Documentation of anamnestic data and therapy sequences</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pancreas Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pancreatic cancer undergoing antineoplastic treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or locally advanced pancreatic cancer

          -  18 years and older

          -  Antineoplastic treatment

        Exclusion Criteria:

          -  No pancreatic cancer

          -  Below 18 years and older

          -  No antineoplastic treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Hegewisch-Becker, Prof. MD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Hofheinz Ralf, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universit√§tsmedizin Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Kopfmann</last_name>
    <phone>+4976115242-0</phone>
    <email>info@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>iOMEDICO</name>
      <address>
        <city>Freiburg</city>
        <state>BW</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic neoplasms</keyword>
  <keyword>neoplasms</keyword>
  <keyword>registry</keyword>
  <keyword>advanced pancreatic cancer</keyword>
  <keyword>health services research</keyword>
  <keyword>epidemiology</keyword>
  <keyword>Germany</keyword>
  <keyword>palliative treatment</keyword>
  <keyword>palliative care</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
